WWA
TXMD icon

Wealth Watch Advisors’s TherapeuticsMD TXMD Stock Holding History

Wealth Watch Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22
Closed -$24 – 1048
2025
Q3 		$24 Buy
+22
New +$25 ﹤0.01% 918

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wealth Watch Advisors's TXMD Position: Q4 2025 in Review

Wealth Watch Advisors sold out of TherapeuticsMD (TXMD) in Q4 2025, closing a stake of 22 shares — an estimated $24 sold.

Wealth Watch Advisors first reported a position in TXMD in Q3 2025 and held it in 1 quarter. The position peaked at $24 in Q3 2025. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2025.

  • Wealth Watch Advisors reported no remaining TherapeuticsMD position as of Q4 2025 after selling out during the quarter.
  • Wealth Watch Advisors sold 22 TherapeuticsMD shares in Q4 2025, an estimated $24.
  • Wealth Watch Advisors first reported a position in TherapeuticsMD in Q3 2025 and held it in 1 quarter.
  • Wealth Watch Advisors's TherapeuticsMD position peaked at $24 in Q3 2025.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2025.

Based on Wealth Watch Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.